Previous close | 172.15 |
Open | 172.15 |
Bid | 168.60 |
Ask | 172.75 |
Strike | 660.00 |
Expiry date | 2025-01-17 |
Day's range | 172.15 - 172.15 |
Contract range | N/A |
Volume | |
Open interest | 304 |
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?